NCT04470726View on ClinicalTrials.gov

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

June 20, 2023

Study Completion Date

July 28, 2023

Conditions
Superficial Basal Cell CarcinomaNodular Basal Cell CarcinomaNonmelanoma Skin Cancers
Interventions
DRUG

AIV001

Intradermal/intratumoral

DRUG

AIV001 suspension

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Trial Locations (4)

78660

Austin Institute for Clinical Research, Pflugerville

92024

California Dermatology & Clinical Research Institute, Encinitas

92117

Skin Surgery Medical Group, San Diego

92660

Island Dermatology, Newport Beach

Sponsors
All Listed Sponsors
lead

AiViva BioPharma, Inc.

INDUSTRY

NCT04470726 - Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype | Biotech Hunter | Biotech Hunter